Delving into the Latest Updates on rLASV-GPC/CD(NIAID) with Synapse

Overview

Basic Info

Drug Type

Live attenuated vaccine, Prophylactic vaccine

Synonyms-

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesOther Diseases

Active Indication-

Inactive Indication

Lassa Fever

Originator Organization

National Institute of Allergy & Infectious Diseases

Active Organization-

Inactive Organization

National Institutes of Health

License Organization-

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

Author: Cooper, Kurt ; Iwasaki, Masaharu ; Liu, David X. ; Yu, Shuiqing ; Nogales, Aitor ; Adams, Ricky ; Brady, Tyler ; St Claire, Marisa ; Postnikova, Elena N. ; Cai, Yingyun ; Hart, Randy ; Martínez-Sobrido, Luis ; Ye, Chengjin ; Kuhn, Jens H. ; de la Torre, Juan Carlos ; Cheng, Benson ; Kurtz, Jonathan

Lassa virus (LASV) infects several hundred thousand people in Western Africa, resulting in many lethal Lassa fever (LF) cases. Licensed LF vaccines are not available, and anti-LF therapy is limited to off-label use of the nucleoside analog ribavirin with uncertain efficacy. We describe the generation of a novel live-attenuated LASV vaccine candidate. This vaccine candidate is based on mutating wild-type (WT) LASV in a key region of the viral genome, the glycoprotein precursor (GPC) gene. These mutations do not change the encoded GPC but interfere with its production in host cells. This mutated LASV (rLASV-GPC/CD) behaves like WT LASV (rLASV-WT) in cell culture, but in contrast to rLASV-WT, does not cause disease in inoculated guinea pigs. Guinea pigs immunized with rLASV-GPC/CD were protected against an otherwise lethal exposure to WT LASV. Our results support the testing of this candidate vaccine in nonhuman primate models ofLF.

100 Deals associated with rLASV-GPC/CD(NIAID)

Login to view more data